Last reviewed · How we verify
NCT04074278
Novel Equations for Estimating Lean Body Mass in Patients With Chronic Kidney Disease
trial in Lean Body Mass in 300 participants. Completed in 1 December 2015.
1 December 2015
Quick facts
| Lead sponsor | Peking University First Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 March 2013 |
| Primary completion | 1 December 2015 |
| Estimated completion | 1 December 2015 |
| Sites | 1 location across China |
Conditions studied
- Lean Body Mass — all drugs for Lean Body Mass →
- Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
Sponsor
Peking University First Hospital
Who can join
Adults 18 to 80, any sex, with Lean Body Mass or Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Simplified methods to estimate lean body mass (LBM), an important nutritional measure representing muscle mass and somatic protein, are lacking in non-dialyzed patients with chronic kidney disease (CKD). Objective: We developed and tested a reliable equations for estimation of LBM in daily clinical practice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04074278
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lean Body Mass
Currently open trials in the same condition.
- NCT05834894 — Does Muscle Mass At Intensive Care Unit Admission Determine Mortality: the Memo Study · active not recruiting
Other Peking University First Hospital trials
Trials by the same sponsor.
- NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
- NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
- NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
- NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
- NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04074278 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
- Last refreshed: 10 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04074278.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing